This week, AcuCort AB announced that Anna Chérouvrier Hansson has been appointed as Business Development Director. This new position is part of AcuCort AB's reinforced focus on business development into new markets through strategic partnerships to support the launch of Zeqmelit®. Anna Hansson brings more than 15 years of experience in business...
LSIF has today completed a significant increase in ownership in SciBase by acquiring 7,5 million shares in an off-market transaction.
Today, Acarix has announced that yet another payer has granted USD 300 in fixed reimbursement for use of the CADScor test. As fixed reimbursement in our view is of major importance for parts of the US business case, it is encouraging to see that a dedicated effort and long-term work now is yielding results.
Today, Acarix announced very good news regarding obtaining the first significant international order in new geographical markets, which is the first step in an expansion into new markets.
Due to our CEO Jan Poulsen being the chairman of the board in Acarix, we refrain from commenting further on this news but refer to the company's press release ...
AcuCort AB is currently in the exercise period of the TO 2 warrant program. LSIF has decided to support the subscription by subscribing for 1 MSEK regardless of the share price. Our motivation is that, in our view, the two LOIs – especially the one with Glenmark – are very strong signals that AcuCort is on track. We believe the...
SciBase issued 2 announcements yesterday. First, an announcement regarding the collaboration with Castle Biosciences, Inc., a leading US-based molecular diagnostics company, and at the same time also announcing, that Castle Biosciences, Inc. will invest 19 MSEK in SciBase and become the second largest shareholder.
At LSIF, we see significant...
AcuCort AB has just now released news regarding signing a LOI with the global pharmaceutical company Glenmark Pharmaceuticals. The LOI covers the distribution and marketing of AcuCort's product Zeqmelit® in six European countries: Germany, the Netherlands, the Czech Republic, Austria, Slovakia, and Ukraine
NOSA Plugs AB announced yesterday the acquisition of Pharmacure Health Care International AB for 27,2 MSEK. To finance this, the company also announced a directed share issue aimed towards institutional and family office investors.
Life Science Invest Fund (LSIF) was invited and took part in this transaction.
In connection with this transaction, NOSA...
Today Acarix posted some exiting news on the reimbursement side, which we regard as very important.
Due to our CEO Jan Poulsen being the chairman of the board in Acarix, we refrain from commenting further on this news instead we encourage you to read the company's official press release here
Earlier this week BiBBInstruments AB announced a disappointing but predictable result of the TO1 subscription rate. With a very modest 18,7% subscription rate, BiBBInstruments AB receives 1,7 MSEK before costs.